USTR published a notice of conforming amendment to a product exclusion in the Section 301 investigation of China's acts, policies, and practices related to technology transfer, intellectual property, and innovation. The notice text was not available; the Federal Register page returned an automated-access notice, so the excluded products, HTS codes, rates and effective date are not stated here.
BIS issued a notice defining the pharmaceutical products and listing the jurisdictions eligible for a zero ad valorem Section 232 tariff rate under Proclamation 11020 of April 2, 2026, covering orphan-indication drugs and associated ingredients, nuclear medicines, plasma derived therapies, fertility drugs, cell therapy products, gene therapy products, antibody drug conjugates, chemical, biological, radiological and nuclear medical countermeasures, and animal health. Products and associated ingredients receive the zero rate if they are of a jurisdiction with a current or forthcoming trade and security framework agreement or meet an urgent U.S. health need.
USTR is making conforming amendments to four product exclusions associated with the Section 301 investigation of China's acts, policies and practices related to technology transfer, intellectual property and innovation, after the USITC implemented changes to HTSUS statistical reporting categories effective July 1, 2026. The conforming amendments in the Annex to the notice are effective as of July 1, 2026. CBP will issue instructions on entry guidance and implementation.